Aakaar Medical Technologies Approves FY26 Financial Results and Reappoints Director
Aakaar Medical Technologies Limited (formerly Aakaar Medical Technologies Pvt.Ltd.) announced key decisions following its Board of Directors meeting held on May 15, 2026. The Board approved the audited financial results for the year ended March 31, 2026, along with the reappointment of a retiring director.The company released its financial performance details for the half year ended March 31, 2026, and the corresponding year-to-date results.
Financial Performance Summary
The audited financial results for the year ended March 31, 2026, reflected a total income of 6,158.21 lacs. Total expenses for the period amounted to 5,364.70 lacs, resulting in a profit before tax of 811.30 lacs.The company achieved an Earnings Per Share (EPS) of 6.10 for the year.
Key financial metrics for the period ended March 31, 2026, and March 31, 2025, are detailed below:
| Particulars | As at Mar 31, 2026 (Audited) | As at Mar 31, 2025 (Audited) |
|---|---|---|
| Share capital | 1,417.28 | 1,042.24 |
| Reserves and surplus | 4,037.78 | 1,283.58 |
| Total Equity & Liabilities | 7,941.66 | 5,415.97 |
| Short-term borrowings | 1,853.43 | 2,273.83 |
| Trade payables (Total outstanding) | 198.48 | 382.13 |
| Current Assets Total | 7,661.21 | 5,183.55 |
The Statement of Assets and Liabilities as of March 31, 2026, showed total assets of 7,941.66 lacs.
Segment Performance and Cash Flow
Aakaar Medical Technologies operates through two segments: Aesthetic Devices & Device consumables and Aesthetic Products.The segment revenue data highlights the company's overall revenue growth:
| Segment | Revenue (Full Year Ended Mar 31, 2026) | Revenue (Full Year Ended Mar 31, 2025) |
|---|---|---|
| Aesthetic Devices & Device consumables | 854.72 lacs | 735.66 lacs |
| Aesthetic Products | 5,303.56 lacs | 2,918.13 lacs |
| Total Revenue | 6,158.28 lacs | 6,696.41 lacs |
Regarding profitability, the segment operating profit for the year ended March 31, 2026, stood at 3,875.90 lacs, compared to 3,535.79 lacs in the previous year.
In terms of cash generation, the net cash flow used in operating activities for the year ended March 31, 2026, was (836.13) lacs, compared to (540.62) lacs for the year ended March 31, 2025.
Directorship and Audit Report
The Board of Directors also approved the reappointment of Mr. Dilip Ramesh Meswani, Non-Independent Director, who is liable to retire by rotation. Mr. Meswani, who is the Managing Director and a Promoter, possesses over 24 years of experience in Medical Aesthetics.M/s. C.B. Mehta & Associates Chartered Accountants, the statutory auditors, issued an Audit Report with an unmodified opinion on the financial results for the half year ended March 31, 2026, and the year-to-date results for the period from April 1, 2025, to March 31, 2026.
AAKAAR Stock Price Movement
On Wednesday, Aakaar Medical Technologies Limited shares edged higher to close at ₹80.3, representing a robust 4.90% gain. The stock saw significant investor interest during the session, trading on a volume of 36,800 shares.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.